Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief ...
Its lead product, GH001, is an inhalable form of 5-MeO-DMT aimed at treating treatment-resistant depression (TRD). GH Research PLC (NASDAQ:GHRS), standing tenth among the best psychedelic stocks to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果